Effects of Selective Cyclooxygenase-2 Inhibitor and Non-Selective NSAIDs on Helicobacter pylori-Induced Gastritis in Mongolian Gerbils
Choon Sang Bhang
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Search for more papers by this authorHak Sung Lee
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Search for more papers by this authorSung Soo Kim
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Search for more papers by this authorHo Jin Song
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Search for more papers by this authorYong Jick Sung
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Search for more papers by this authorJin Il Kim
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Search for more papers by this authorCorresponding Author
In Sik Chung
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Reprint request to: In Sik Chung, Division of Gastroenterology, Department of Internal Medicine, The Catholic University of Korea, Kangnam St. Mary’s Hospital, # 505, Banpo-Dong, Seocho-Ku, Seoul, Korea.Search for more papers by this authorHee Sik Sun
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Search for more papers by this authorDoo Ho Park
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Search for more papers by this authorYoun Soo Lee
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Search for more papers by this authorChoon Sang Bhang
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Search for more papers by this authorHak Sung Lee
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Search for more papers by this authorSung Soo Kim
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Search for more papers by this authorHo Jin Song
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Search for more papers by this authorYong Jick Sung
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Search for more papers by this authorJin Il Kim
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Search for more papers by this authorCorresponding Author
In Sik Chung
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Reprint request to: In Sik Chung, Division of Gastroenterology, Department of Internal Medicine, The Catholic University of Korea, Kangnam St. Mary’s Hospital, # 505, Banpo-Dong, Seocho-Ku, Seoul, Korea.Search for more papers by this authorHee Sik Sun
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Search for more papers by this authorDoo Ho Park
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Search for more papers by this authorYoun Soo Lee
Division of Gastroenterology, Department of Internal Medicine, and * Department of Pathology, The Catholic University of Korea, Seoul, Korea
Search for more papers by this authorAbstract
Background. It is still a point of controversy whether Helicobacter pylori-infected patients are more likely to develop mucosal damage while taking NSADIs. Selective cyclooxygenase (COX-2) inhibitors may be associated with less severe gastric mucosal damage than conventional NSAIDs, but this association is undefined in H. pylori-induced gastritis. The aim of this study was to evaluate the effects of selective COX-2 and nonselective NSAIDs on H. pylori-induced gastritis.
Methods. After intragastric administration of indomethacin, NS-398 or vehicle alone, once daily for 5 days in H. pylori-infected and uninfected Mongolian gerbils, we evaluated gastric mucosal damage, inflammatory cell infiltration and prostaglandin E2 (PGE2) concentration. We investigated whether H. pylori infection induced the COX-2 expression.
Results. In H. pylori-uninfected groups, the indomethacin-treated group showed the highest mucosal damage score and the lowest PGE2 concentration. There was no difference in mucosal damage scores and PGE2 concentration between NS-398 and vehicle-alone treated group. In H. pylori-infected groups, there was no difference in mucosal damage scores, irrespective of the type of drugs administered. The indomethacin-treated group showed the lowest PGE2 concentration, similar to that of the NS-398 and vehicle-alone treated groups, both without H. pylori infection. Gastric neutrophil and monocyte infiltration scores were higher in H. pylori-infected groups than in uninfected groups. However, there was no difference in these scores according to the type of drugs administered, within H. pylori-infected or uninfected groups. COX-2 protein expression was observed in H. pylori-infected Mongolian gerbils but not in uninfected ones.
Conclusions. Our animal study showed that H. pylori infection induced COX-2 expression and increased prostaglandin concentration. Administration of NSAIDs decreased the prostaglandin concentration, but did not increase mucosal damage in H. pylori-induced gastritis. Selective COX-2 inhibitors, instead of conventional NSIADs, had no beneficial effect on preventing mucosal damage in H. pylori-induced gastritis.
References
- 1 Smoot DT. How does Helicobacter pylori cause mucosal damage? Gastroenterology 1997; 113: S31–4.
- 2 Ernst PB, Crowe SE, Reyes V. How does Helicobacter pylori cause mucosal damage? The inflammatory response. Gastroenterology 1997; 113: S35–42.
- 3 Laine L, Cominelli F, Sloane R, et al. Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double-blind trial. Aliment Pharmacol Ther 1995; 9: 127–35.
- 4 Sawaoka H, Kawano S, Tsuji S, et al. Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa. Prostaglandins Leukot Essent Fatty Acids 1998; 59: 313–6.
- 5 Zarrilli R, Tuccillo C, Santangelo M, et al. Increased COX-2, but not COX-1, mRNA expression in Helicobacter pylori gastritis. Am J Gastroenterol 1999; 94: 3376–8.
- 6 Lee A, O’Rouke J, De Ungria MC, et al. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 1997; 112: 1386–97.
- 7 Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. Am J Surg Pathol 1996; 20: 1161–81.
- 8 Lee M, Aldred K, Lee E, et al. Aspirin-induced acute gastric mucosal injury is a neutrophile-dependent process in rats. Am J Physiol 1992; 263: G920–6.
- 9 Weiner GJ, Kaminski MS. Anti-idiotypic antibodies recognizing stable epitopes limit the emergence of idiotype variants in a murine B cell lymphoma. J Immunol 1990; 144: 2436–45.
- 10 Hirayama F, Takagi S, Kusuhara H, et al. Induction of gastric ulcer and intestinal metaplasia in Mongolian gerbils infected with Helicobacter pylori. J Gastroenterol 1996; 31: 755–7.
- 11 Ikeno T, Ota H, Sugiyama A, et al. Helicobacter pylori-induced chronic gastritis, intestinal metaplasia, and gastric ulcer in Mongolian gerbils. Am J Pathol 1999; 154: 951–60.
- 12 Wallace JL. Prostaglandins NSAIDs, and cytoprotection. Gastrointestinal Pharmacol 1992; 21: 631–41.
- 13 Xie W, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: a new target for nonsteroidal antiinflammatory drugs. Drug Dev Res 1992; 25: 249–65.
- 14 Masferrer JL, Zweifel BS, Manning PA, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammtory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228–32.
- 15 Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91: 12013–7.
- 16 NIH. Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65–9.
- 17 Martin DF, Montgomery D, Dobek AS, et al. Campylobacter pylori, NSAIDs and smoking: risk factors for peptic ulcer disease. Am J Gastroenterol 1989; 84: 1268–72.
- 18 Heresbach D, Raoul JL, Bretagne JF, et al. Helicobacter pylori: a risk and severity factor of non-steroidal anti-inflammatory drug induced gastropathy. Gut 1992; 33: 1608–11.
- 19 Santucci L, Fiorucci S, Patola L, et al. Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of serum pepsinogens. Dig Dis Sci 1995; 40: 2074–80.
- 20 Taha AS, Sturrock RD, Russel RI. Mucosal erosions in longterm non-steroidal anti-inflammatory drug users; predisposition and relation to Helicobacter pylori. Gut 1995; 36: 334–6.
- 21 Lanza FL, Evans DG, Graham DY. Effect of Helicobacter pylori infection on the severity of gastroduodenal mucosal injury after the acute administration of naproxen or aspirin in normal volunteers. Am J Gastroenterol 1991; 86: 735–7.
- 22 Thillainayagam AV, Tabaqchali S, Warrington SJ, et al. Interrelationships between Helicobacter pylori infection, nonsteroidal antiinflammatory drugs and gastroduodenal disease. A prospective study in healthy volunteers. Dig Dis Sci 1994; 39: 1085–9.
- 23 Graham DY, Lidsky MD, Cox AM, et al. Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection. Gastroenterology 1991; 100: 1653–7.
- 24 Wu CY, Poon SK, Chen GH, et al. Interaction between Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding. Scan J Gastroenterol 1999; 34: 234–7.
- 25 Varanasi RV, Ramanujam KS, Wilson KT. A soluble factor from Helicobacter pylori induces expression and activity of cyclooxygenase-2. Gasgtroenterology 1998; 114: A1107.
- 26 FUS, Ramanujam KS, Wong A, et al. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygense 2 in Helicobacter pylori gastritis. Gastroenterology 1999; 116: 1319–29.
- 27 Arias-Negrete S, Keller K, Chadee K. Proinflammatory cytokines regulate cyclo-oxygenase-2 mRNA expression in human macrophages. Biochem Biophys Res Commun 1995; 208: 582–9.
- 28 Takahashi S, Fujita T, Yamamoto A. Nonsteroidal anti-inflammatory drug-induced acute gastric injury in Helicobacter pylori gastritis in Mongolian gerbils. Eur J Pharmacol 2000; 406: 461–8.
- 29 The European Helicobacter pylori Study Group (EHPSG). Current European concepts in the management of H.Pylori Infection: Maastricht Consensus Report Gut 1997; 41: 8–13.
- 30 Seppala K, Pikkarainen P, Sipponen P, Kivilaakso E, Gormsen MH. Cure of peptic gastric ulcer associated with eradication of Helicobacter pylori. Gut 1995; 36: 834–7.
- 31 Chan FK, Sung JJ, Chung SC, et al. Randomized trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 975–9.
- 32 Bianchi Porro G, Parente F, Imbesi V, et al. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy. Gut 1996; 39: 22–6.
- 33 Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter eradication for lesion prevention. Lancet 1998; 352: 1016–21.
- 34 Yeomans ND, for the Omeprazole NSAID Steering Committee. New data on healing of NSAID-associated ulcers, erosions. Am J. Med 1998; 104: 56S–61S.
- 35 Hawkey CJ, for the Omeprazole NSAID Steering Committee. Progress in prophylaxis against NSAID-associated ulcers, erosions. Am J. Med 1998; 104: 67S–74S.
- 36 Pilotto A, Di Mario F, Franceschi M, et al. Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. Aliment Pharmacol Ther 2000; 14: 1077–82.
